Betahistine or cinnarizine with or without dimenhydrinate for Ménière’s disease/syndrome and symptoms of vestibular vertigo and/or tinnitus

In Switzerland, betahistine and cinnarizine are reimbursed by the mandatory health insurance for patients experiencing symptoms of vertigo, tinnitus, and hearing loss caused by conditions such as Ménière’s Disease and others. Cinnarizine combined with dimenhydrinate is reimbursed for the symptomatic treatment of transient vertigo. The clinical effectiveness of these drugs is unclear.

The aim of the HTA report is therefore to assess the effectiveness, appropriateness, and economic efficiency of these treatments in patients with Ménière’s Disease or Syndrome, vestibular vertigo or tinnitus.

Dokumente

HTA protocol (PDF, 359 kB, 08.03.2024)

Stakeholder feedback on the scoping report (version 1) (PDF, 112 kB, 08.03.2024)

Stakeholder feedback on the scoping report (version 2) (PDF, 152 kB, 12.04.2024)

< back to HTA projects

Last modification 08.03.2024

Top of page

Contact

Federal Office of Public Health FOPH
Health insurance benefits Division
Health Technology Assessment Section
Schwarzenburgstrasse 157
3003 Bern
Switzerland
Tel. +41 58 469 17 33
E-mail

Print contact

Main Navigation

FOPH

Search

Breadcrumb

Betahistine or cinnarizine with or without dimenhydrinate for Ménière’s disease/syndrome and symptoms of vestibular vertigo and/or tinnitus

Dokumente

Contact